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Abstract
Despite the conventional view that a truly random V(D)J recombination process should generate a highly diverse immune 
repertoire, emerging reports suggest that there is a certain bias toward the generation of shared/public immune receptor 
chains. These studies were performed in viral diseases where public T cell receptors (TCR) appear to confer better protective 
responses. Selective pressures generating common TCR clonotypes are currently not well understood, but it is believed that 
they confer a growth advantage. As very little is known about public TCR clonotypes in cancer, here we set out to determine 
the extent of shared TCR clonotypes in the intra-tumor microenvironments of virus- and non-virus-driven head and neck 
cancers using TCR sequencing. We report that tumor-infiltrating T cell clonotypes were indeed shared across individuals 
with the same cancer type, where the majority of shared sequences were specific to the cancer type (i.e., viral versus non-
viral). These shared clonotypes were not particularly enriched in EBV-associated nasopharynx cancer but, in both cancers, 
exhibited distinct characteristics, namely shorter CDR3 lengths, restricted V- and J-gene usages, and also demonstrated 
convergent V(D)J recombination. Many of these shared TCRs were expressed in patients with a shared HLA background. 
Pattern recognition of CDR3 amino acid sequences revealed strong convergence to specific pattern motifs, and these motifs 
were uniquely found to each cancer type. This suggests that they may be enriched for specificity to common antigens found 
in the tumor microenvironment of different cancers. The identification of shared TCRs in infiltrating tumor T cells not only 
adds to our understanding of the tumor-adaptive immune recognition but could also serve as disease-specific biomarkers 
and guide the development of future immunotherapies.
Keywords T cell receptor · Immune repertoire sequencing · Tumor-infiltrating T cells · Public TCR  · TCR sharing
Background
The collective expression of different T cell receptors (TCR) 
in an individual, known as the TCR repertoire, is central 
to each person’s ability to recognize a vast range of patho-
gens and to initiate specific adaptive immune response. Each 
TCR consists of a heterodimer of two chains (either α + β 
or γ + δ), each generated through random rearrangement of 
germline variable (V), diversity (D) and joining (J) segments 
and the non-templated insertion and deletion of nucleotides 
at the V(D)J junctions. Although the theoretical estimate of 
the diversity of the TCR is more than 1 ×  1015 [1], only about 
 106–107 unique TCRβ chains are expressed in approximately 
 1012 circulating T cells from healthy adults [2, 3]. T cells 
are activated and driven to clonally expand upon antigenic 
stimulation, with some formation of memory subsets that 
persist for long periods. Hence, the TCR repertoire not only 
reflects the current state of the adaptive immune system, but 
also provides an immunological footprint of its past history.
Despite the low expected likelihood of having two indi-
viduals that share the same TCR sequences, there are con-
sistent observations that a small fraction of TCR chains, also 
known as public TCRs, are shared between different individ-
uals, both in mice [4, 5] and humans [4, 6, 7]. This phenom-
enon is detectable in circulating blood of healthy adults [6, 
7] and also encompasses public T cell responses to viruses 
[8, 9] and auto-immune diseases [10–12]. The selection of 
public TCRs appears to confer improved T cell survival in 
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certain circumstances. For example, in human immunodefi-
ciency virus (HIV), public TCRs are found in a population 
of HIV-responsive CD8 and CD4 T cells [9]. HIV-associated 
public TCRs are endowed with features of high avidity and 
cross-reactivity, both major determinants of antiviral effi-
cacy. Similarly, the T cell response to other human viral 
diseases such as Epstein–Barr virus (EBV), cytomegalovirus 
(CMV) and influenza virus is peculiarly limited among indi-
viduals with the same MHC haplotypes [13]. There is clearly 
a need to fully understand the processes that bias toward the 
production of public TCRs, whose functional consequences 
may have important translational applications.
In the domain of tumor immunology, there were some 
early reports to indicate sharing of TCR clonotypes in 
tumors using earlier technologies [14–16], but a comprehen-
sive analysis of TCR sharing across tumor types and exami-
nation of their characteristics has been limited. Undoubtedly, 
the identification of these common sequences would have 
a number of important consequences. First, these could be 
used to trace common immune histories across patients with 
the same cancer types in order to understand disease biol-
ogy. Second, targeting universally shared TCR clonotypes 
could be an important approach in future TCR-based gene 
or cellular immunotherapy. Finally, disease-specific public 
TCRs could lead to the development of biomarkers specific 
to disease states.
In this study, we sought to determine the extent of shared 
TCR clonotypes in the intra-tumor microenvironment of 
two different head and neck cancer types: EBV-linked naso-
pharyngeal carcinoma (NPC) and non-virally linked head 
and neck squamous carcinomas (HNSCC). We hypoth-
esized that public clonotypes may be more abundant in the 
virus-driven cancers like NPC compared to non-virus-driven 
cancers, as a result of selection for TCR clones consequent 
to persistent viral insults to the tumor environment.
Results
Targeted T cell receptor sequencing for the TCRβ chain was 
performed on RNA samples from 19 NPC patients and 10 
HNSCC patients; the former cohort were all confirmed to be 
positive for EBV, while the latter were negative for EBV or 
HPV. The clinical characteristics of these patients are shown 
in Supplementary Table 1. The quality, filtering and analysis 
of the TCR sequencing data are described in Supplemen-
tary Table 2 and Methods. We obtained on average 330,578 
productive TCR reads per sample (range 6716–1,150,255), 
after correcting for duplication and sequencing errors, and 
using only unique barcoded reads aligned against the TCRβ 
sequences from the ImMunoGeneTics (IMGT) database. Of 
these productive reads, an average of 32,599 unique CDR3 
clonotypes per sample were obtained per sample (range 
1446–164,463). TCR clonotypes were defined here as TCR 
sequences sharing the same CDR3 amino acid sequence and 
the same V- and J-gene region. Whilst we did not exhaus-
tively capture the full TCR repertoire from these patients, 
this level of TCR sequencing depth can allow for detailed 
analysis of public clonotypes (Supplementary Figure 1).
We next determined whether we could identify unique, 
tumor-specific TCRs within the microenvironment of each 
cancer type. We calculated the extent of clonal overlap 
between any two samples using Jaccard similarity index: 
the majority of each TCR repertoire was unique to its sam-
ple (average Jaccard index: 0.0007). However, a subset 
of TCRs were present in multiple samples (Fig. 1a). The 
extent of TCR sharing in each cancer type was determined 
by examining the number of private and shared CDR3s 
found across different patients within that type. There were 
5878 and 1060 TCRs found in at least two NPC and two 
HNSCC patients, respectively (Fig. 1b). Subsequently, in 
our study, we defined as shared TCR clonotypes those clo-
notypes with the same CDR3 amino acid sequence, V-gene 
and J-gene, and present in at least 30% of the patients in 
each cancer cohort. Each sample had to have at least two 
uniquely barcoded TCR reads for each TCR clonotype to be 
confidently deemed present. There were a total of 49 shared 
TCR clonotypes found in our NPC cohort and 67 shared 
TCR clonotypes in the HNSCC samples. Out of these, only 3 
TCRs were found shared in both cancer types. The baseline 
frequency of shared TCRs was calculated from the number 
of shared TCRs each patient expressed as a percentage of the 
total number of unique clonotypes found in each patient. We 
found that there was no statistical difference between the two 
cancer types with an average of 0.002% for virally driven 
Fig. 1  Sharing of TCR clonotypes is common across patients in two 
different cancers. a Jaccard similarity matrix of TCR clonal over-
lap between samples. Boxes shaded in gray are similarities between 
self. b Number of shared TCR clonotypes found between number of 
patients. x-axis: Log2(counts + 1) of shared TCRs found in any num-
ber of patients (y-axis). c Baseline frequency of shared TCR clono-
types (found in each cancer type or in both cancer types) over total 
number of unique clonotypes per sample. d Frequency of shared 
TCR clonotypes per patient. Colors represent the number of patients 
that share the same TCR clonotype within the cancer cohort. Shapes 
represent TCR clonotypes found uniquely within a single cancer 
type, in both cancers or found in an independent cohort of healthy 
individuals. e Proportion of shared TCRs that are found in healthy 
donors, single cancer type or both cancer types. f Frequency of high-
frequency clonally expanded TCRs per patient. Legend same as 1D. 
g Proportion of private, less shared, shared TCR clonotypes in the 
high-frequency clonally expanded TCRs. h CDR3 length distribu-
tion of private (green), less shared (red) and shared (blue) TCRs. i V- 
and J-gene usage heatmap of shared TCR clonotypes. Fold-change in 
V + J use between shared and private TCRs. j Number of nucleotides 
coding for each shared TCR clonotype. Each dot represents a single 
shared TCR. X-axis: number of patients each shared TCR found in. 
y-axis: number of nucleotides found in each cohort that codes for 
same shared TCR 
◂
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NPC compared to 0.004% for HNSCC (p = 0.16, Fig. 1c). 
The median baseline frequency of shared TCRs that were 
found common in both cancers was 0.001% across all sam-
ples. These results suggest that contrary to our hypothesis, 
the presence of persistent viral stimulation does not contrib-
ute to the selection of more public TCR clonotypes.
To determine whether these shared TCR clonotypes could 
result from recent exposures to antigenic stimulation, the 
clonal frequency of shared TCRs in individual samples was 
plotted to determine their clonal sizes (Fig. 1d). Of the total 
number of different shared TCRs each patient expressed 
from both cancer cohorts, 83.7% of shared TCRs were 
small clones with frequency of less than 0.1% (Supplemen-
tary Table 3). However, there were 10 HNSCC TCR clones 
and 12 NPC TCR clones that were dominantly expanded 
in a few samples, with clonal frequencies of more than 5%. 
We next asked if these shared CDR3s were cancer-specific 
and searched for these clonotypes in an independent, large 
cohort of TCR sequences obtained from the blood of nor-
mal healthy adults [6, 17] and found that only 22 of all the 
shared TCR clonotypes in both cancers (n = 116) were found 
in the blood of healthy donors. Remarkably, the majority of 
the shared TCRs could only be found within each cancer 
type (69.4% NPC-only and 80.6% HNSCC-only, Fig. 1e, 
Supplementary Table 3) and 50 of these shared TCRs were 
significantly enriched in each cancer group (p value < 0.05) 
(Supplementary Table  4), suggesting that these tumor-
specific shared TCRs may be driven by common antigens 
found uniquely within each cancer type. Conversely, high-
frequency, clonally expanded TCRs (Supplementary Fig-
ure 2A, 2B, prevalence more than 1% clonal frequency in 
each tumor), tend to be private and less shared (84.7% in 
NPC and 65.8% in HNSCC) (Fig. 1f, g), suggesting that the 
high-frequency TCR clones are predominantly tumor- and 
individual-specific and may represent a more recent patient-
tumor-specific antigenic event.
Certain TCR traits such as CDR3 length, V- and J-gene 
usages are distinctive in some infectious or auto-immune 
diseases. For example, type 1 diabetic patients were found 
to have shorter CDR3 regions [18], and restrictions in 
V- and J-gene usages were found common in public TCR 
clonotypes to viral antigens [19]. We therefore queried if 
the public TCR clonotypes identified here presented simi-
lar features. For this and subsequent analyses, we removed 
shared TCR clonotypes that were also found in the cohort 
of healthy donors and only analyzed cancer patient-specific 
clonotypes. Shared TCRs in both cancer cohorts had shorter 
CDR3 sequence lengths compared to private TCRs (13 ver-
sus 15 amino acids, respectively) (Fig. 1h). Moreover, there 
were significantly different V- and J-gene usages between 
the two groups. In particular, TRBV13-TRBJ2-6 was used 
21 times more commonly in shared HNSCC TCRs vs private 
HNSCC TCRs, and TRBV13-TRBJ1-1/-4/-5 were used 7 
times more commonly in shared NPC TCRs vs private NPC 
TCRs (Fig. 1i). Both cancers also exhibited preferential V- 
and J-gene usages within each cancer type. Lastly, we asked 
whether shared TCRs display a higher level of convergent 
recombination, as seen in other reports [5]. Increased shar-
ing was associated with an increasing number of nucleotides 
that encode the same CDR3 sequence (Fig. 1j). This was 
seen in both cancers, demonstrating a high level of conver-
gent recombination driving the selection of these public 
TCR clonotypes.
Given the obvious association between antigen presen-
tation and HLA subtypes, we next set out to examine the 
relationship (if any) between HLA types and the public 
intra-tumoral TCR clonotypes identified here. HLA typ-
ing for each patient is shown in Supplementary Table 5. To 
determine the association, we first calculate the percentage 
of patients with the same HLA alleles over the total number 
of patients expressing that shared TCR, for each public TCR 
clonotype at each HLA allele. We then counted the number 
of TCRs that were shared and expressed in patients with 
different percentages of HLA sharing (Fig. 2a). For exam-
ple, there were 24 TCR clonotypes in HNSCC patients that 
had at least 75% patients with the same HLA-DRB1*12:02 
background (Fig. 2b). Notably, there were a total of 36 pub-
lic TCR clonotypes that were shared in more than 75% of 
HNSCC patients with the same HLA background, while 
there was only 1 such public TCR clonotype in the NPC 
cohort (Supplementary Table 6a, 6b).
Much of the data thus far support the notion that intra-
tumor shared TCR clonotypes converge on shared tumor-
specific antigens. To test this hypothesis further, we extended 
the actual amino sequences to motif signatures for each of 
the TCR clonotypes using GLIPH2 (grouping of lymphocyte 
interaction by paratope hotspots version 2) [20]. Interest-
ingly, we identified 8 and 6 shared motifs in HNSCC and 
NPC clonotypes, respectively, all of which were tumor-type-
specific (representative motifs shown in Fig. 2c; detailed 
motif search shown in Supplementary Table 7a, 7b).
Finally, the intra-tumoral public TCR clonotypes iden-
tified here were compared with TCR sequences against 
known antigens. To do this, we obtained TCRβ sequences 
from public databases, VDJDB [21] and McPAS [22], 
which contain TCRs associated with different viruses, 
auto-immune diseases and tumors. We found that only 6 
TCR clonotypes had the exact CDR3, V-, J-gene and HLA 
match to those in the databases, and these were associ-
ated with common viruses like CMV, EBV and influenza 
(Supplementary Table 8), while one had a match to an 
antigen epitope from colorectal cancer. We next searched 
for common motifs between the shared TCR clonotypes 
with those from the public databases and found 92 and 
83 common motifs in the HNSCC and NPC cohorts that 
converged with TCRβ sequences associated predominantly 
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with viruses like CMV, EBV, HCV, HIV-1 and Influenza 
(Fig. 2d, Supplementary Table 9a, 9b). The heatmap shows 
that there is a NPC-specific cluster (Clusters 2a and 2b) 
that overlaps with the part of the viral cohort, while a 
separate and distinct HNSCC cluster (Clusters 3a and 3b) 
demonstrates another group of motifs, which overlaps a 
different set of the viral cohort. Interestingly, these also 
overlap with common motifs found in the general tumor 
neoantigens and highly antigenic melanoma cohorts, but 
not with specific cancer types like leukemia and lym-
phoma. Separately, the identification of common motifs 
across TCR sequences from different viruses, self-anti-
gens and tumor (Cluster 1) may support future work on 
understanding the roles of shared TCR clonotypes in the 
concept of TCR cross-reactivity.
Discussion
In this study in two cancer types with different etiologies, we 
found that each tumor-type harbors a set of cancer-specific 
public TCR clonotypes that contain distinct features from 
private TCRs. Previous studies have identified the existence 
of shared TCR clones in the intra-tumoral microenviron-
ment [14–16], yet the characteristics of these remain unclear. 
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Fig. 2  Public TCR clonotypes converge on motif signatures that are 
unique to cancers. a Number of shared TCRs in patients express-
ing same HLA alleles. X-axis: percentage of patients with same 
HLA = Patients with same HLA type and expressing same shared 
TCR/total number of patients expressing same shared TCR. Y-axis: 
number of shared TCRs. Color represents cancer cohort. b Inset dia-
gram of shared TCRs that are shared in more than 75% of patients 
with the same HLA-types. c Representative convergent motifs found 
in shared TCR clonotypes that are specific to each cancer type. Black 
box: HNN Red box: NPC. Blue number on top left of box reveals 
total number of patients who have convergent TCRs. Red number on 
bottom right of box shows total number of different TCRs that con-
tain that motif. d Heatmap of motif convergence to TCR sequences 
from public databases. Y-axis is individual motif patterns. X-axis is 
source of database. Red denotes convergence, while blue denotes 
non-convergence
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microenvironment have distinctive characteristics: shorter 
CDR3 lengths and restricted V- and J-gene usages, display 
convergent recombination and demonstrate a high level of 
converging motif signatures. These are surprisingly over-
lapping with previously published studies on public TCRs 
observed from circulating blood of healthy humans [6, 23, 
24], infants [25] and mice [5, 26] and suggest a common 
underlying mechanism and function for public TCR con-
vergence, yet the motifs and sequences identified here also 
show cancer-type specificity.
The phenomenon of immune convergence is not only seen 
in the T cell-mediated response, but also frequently extends 
to B cells. These are well-described in infectious diseases, 
auto-immune diseases but less in cancer. For example, con-
verging TCR sequences were identified in healthy donors 
exposed to cytomegalovirus (CMV), Epstein–Barr virus 
(EBV), mycobacterium tuberculosis (TB), influenza and the 
yellow fever virus YV-17D vaccine [27–30]. In HIV, TCR 
repertoire analysis revealed that rare patients who controlled 
their HIV well showed a highly skewed TCR repertoire 
that was characterized by a predominance of TRAV24 and 
TRBV2 variable genes, shared CDR3 motifs, and a high fre-
quency of public clonotypes [9]. The most prevalent public 
clonotypes generated TCRs with high binding affinities and 
are associated with superior functions that control HIV well. 
Recently, analysis of the B-cell receptor repertoire in con-
valescent blood of recovered COVID-19 patients revealed 
expanded clones of receptor-binding domain (RBD)-specific 
memory B cells (toward SARS-CoV-2 Spike protein (S)) 
expressing closely related antibodies in different individu-
als [31]. There was high neutralization efficacy of these 
antibodies to three distinct epitopes on RBD. A separate 
study also showed a high preference for the IGHV3-53 gene 
as the most frequently used IGHV gene for targeting the 
receptor-binding domain (RBD) of the SARS-CoV-2 spike 
protein [32]. Several mechanisms including structural bias 
or convergent recombination have been proposed to explain 
the public immune responses. Regardless of the evolution-
ary driver, these studies consistently signify a selective 
advantage for the convergence of the T or B cell repertoire 
across individuals, one that is geared toward a more effec-
tive immune response. Future studies investigating public 
TCRs shared across cancers may provide insights into the 
clonotypes that may mediate desirable immune responses 
toward malignancy.
Our data also show many of the motifs we identified were 
common between public tumor TCR clonotypes and those 
with viral and neoantigen-associated TCR sequences from 
public databases. Combined with observations that shorter 
CDR3s were also found to be highly enriched in antigen-
experienced memory T cells [24, 33], we postulate that the 
public TCR clonotypes observed in the tumor microenvi-
ronment could be memory T cells that were either selected 
for after past encounters with viruses or tumor neoantigen 
within the tumor environment, or are virus-specific memory 
T cells extending their surveillance in the tumors. Never-
theless, this could present a window of opportunity to re-
activate known antiviral T cells in the tumor and a unique 
therapeutic approach for cancer immunotherapy. Rosato 
et al. have concluded a proof-of-concept study where they 
reactivated surveillant antiviral T cells by injecting adjuvant-
free non-replicating viral peptides into tumors explanted in 
mice [34]. They showed that viral peptide treatment mimics 
a viral reinfection event to memory CD8 + T cells and arrest 
the growth of checkpoint blockade-resistant and poorly 
immunogenic tumors. Similarly, delineating the antigen 
repertoire recognized by intra-tumoral bystander T cells 
through TCR sequencing could pave the way to re-direct 
these to target the tumor instead.
Interestingly, majority of the shared TCR clonotypes in 
each cancer was specific to the cancer type and converged to 
similar motifs that were unique to each cancer. This suggests 
a shared immune background specific to different cancers 
and may reveal an antigenic footprint of common etiology 
unique to each. In addition, this presents a unique circum-
stance to identify cancer-specific TCR sequences, which can 
be further developed into TCR-based diagnostics that can 
be used to track and monitor diseases. Viral-specific TCR 
sequences have been discovered [17, 35], and future work 
can be extended into cancer studies.
We acknowledge that future studies can examine the 
TCRα chain sequence pairing to fully understand the anti-
gen-binding specificity of each shared TCR. Public TCRα 
sequences have also been found at high frequencies in multi-
ple individuals [36, 37]. However, only single-cell sequenc-
ing is able to fully recapitulate the extent of public paired 
TCRαβ chain, which is an expensive endeavor. In addition, 
the unsaturated sequencing depth achieved in this study lim-
its the discovery of more low-frequency shared TCR clono-
types and the baseline frequency of shared TCRs reported 
here could be an under-representation of the true extent of 
TCR sharing in tumors. In spite of these limitations, we pre-
sent this study to first highlight the extent of public TCR 
sharing in the tumor microenvironment and their distinct 
characteristics, to show that selective pressures act in the 
tumor to drive the TCR repertoire to convergent signatures, 
which may be beneficial for future analysis and development 
of diagnostic and therapeutic applications.
Conclusions
In this study, we discovered that TCRs are shared in the 
tumor microenvironment across multiple patients within two 
different head and neck cancer subtypes: EBV-linked naso-
pharyngeal carcinoma (NPC) and non-virally linked head 
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and neck squamous carcinomas (HNSCC). These shared 
TCRs consistently display features of shorter CDR3 lengths, 
restricted V- and J-gene usages and demonstrate convergent 
recombination. They were also expressed in patients with 
a common HLA background. Most strikingly, these shared 
tumor TCRs were unique to each cancer-type and revealed 
specific cancer-type motif signatures. This study provides 
a useful resource for the future development of TCR-based 
cancer diagnostics or therapeutics.
Materials and methods
Patient samples
Tumor tissues were obtained from patients with head and 
neck squamous cancers (HNSCC) or nasopharyngeal can-
cers (NPC) undergoing resection surgery at National Cancer 
Centre Singapore (NCCS) after obtaining informed consent. 
All protocols were reviewed and approved by the Institu-
tional Review Board (IRB) at NCCS. Samples were col-
lected from 10 HNN patients and 19 NPC patients spanning 
stage II–IV disease. Clinical information of all patients is 
annotated in Supplementary Table 1.
TCR sequencing
RNA was extracted from tissue biopsies of all patient sam-
ples using Qiagen AllPrep DNA/RNA Mini Kit (Qiagen). 
The TCR libraries were prepared according to previous pub-
lished method [38]. MiSeq libraries were prepared using 
Illumina protocols and sequenced using 300-bp paired-end 
MiSeq kits (Illumina).
TCR repertoire analysis
Raw MiSeq forward and reverse reads were merged using 
published Paired-End reAd mergeR (PEAR) tool. Universal 
barcoded regions were identified in each read using the fol-
lowing sequence: TNNNNTNNNNTNNNNT. Reads with 
identical universal barcode regions were condensed into a 
single read, and primers and constant regions were trimmed 
from all reads. Sequences were annotated using the reference 
TRBV, D- and J-genes from the IMGT database with IMGT/
HighV-QUEST tool [39]. Non-TCR reads and non-produc-
tive TCR rearrangements were removed for further analysis.
Clonal overlap analysis
Clonal overlap analysis was performed by calculating the 
Jaccard similarity index between two samples, where a 
minimum of two unique barcoded reads must be present to 
be determined as present. The Jaccard index is calculated as:
where J is the Jaccard similarity index, X, Y = number 
of TCR clonotypes present in dataset X, Y and |X ∩ Y| rep-
resents the number of TCR clonotypes found in both X, Y 
datasets. Dendrogram clustering was performed using hclust 
method in R, with ‘complete’ linkage method.
HLA typing
HLA genotypes of all NPC samples and HNSCC samples, 
except for HNN220 and HNN228, were obtained from avail-
able aligned reads from RNAseq data. ArcasHLA tool [40] 
was then used to extract and define HLA genotypes, where 
IMGT-HLA database version 3.39 was used as the refer-
ence database. Whole exome sequencing data (WES) but 
not RNAseq data were available for HNN220 and HNN228 
and were used to extract HLA reads using HLA-HD [REF]. 
There were no available WES/RNAseq/HLA data for 
NCC010, NCC014, NCC022 and NCC028. Only HLA-A, 
HLA-B, HLA-C, HLA-DPA1, HLA-DPB1, HLA-DQA1, 
HLA-DQB1 and HLA-DRB1 were analyzed in this study.
Motifs searching
To look for common motif signatures, we used the published 
method, Grouping of Lymphocyte interactions by paratope 
hotspots version 2-Gliph2 [20], through the web service: 
http:// 50. 255. 35. 37: 8080. The CD4/8 reference option was 
used, together with all other default options.
Curation of public databases
TCRβ sequences were extracted from two public databases, 
VDJDB [21] and McPAS [22]. We selected all sequences 
associated with human species and specific to viruses, 
allergy and cancer.
Statistical tests
All statistical analyses were performed using R version 3.6.3 
and associated packages. Kolmogorov–Smirnov test was 
performed to determine the significance of the distribution 
of CDR3 lengths between the private, less shared and shared 
TCRs. Wilcoxon test was used to compare statistical signifi-
cance between two groups. Rarefaction analysis of estimated 
species richness was performed using the R package, rtk 
[41]. Fisher’s exact test was used to examine the association 
of specific shared TCRs within cancer groups.
J(X, Y) =
|X ∩ Y|
|X| + |Y| − |X ∩ Y|
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Supplementary Information The online version contains supplemen-
tary material available at https:// doi. org/ 10. 1007/ s00262- 021- 03047-7.
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